The differential functional protein COPB2 is expected to become a new biomarker for PCa diagnosis and monitoring, and studying it may provide a theoretical basis for identifying effective drug intervention targets through in-depth mechanistic studies. Here, COPB2 is linked to posterior cortical atrophy.